Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Single Rising Doses of BI 705564 in Healthy Males
NCT03747926Phase 1Withdrawn
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2019
- Primary completion
- Aug 2019
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, single-blind trial of BI 705564 in systemic lupus erythematosus (SLE), sponsored by Boehringer Ingelheim. Primary endpoint: Number of subjects with drug-related Adverse Events. Planned start Apr 2019; status: withdrawn.
02
Drugs
BI 705564
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT03747926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03747926.